Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 417.31M | 246.37M | 158.96M | 56.15M | 13.10M |
Gross Profit | 225.06M | 144.37M | 102.92M | 36.94M | 11.37M |
EBITDA | -260.05M | -320.62M | -359.98M | -371.30M | -2.26B |
Net Income | -268.27M | -379.79M | -402.64M | -134.78M | -2.26B |
Balance Sheet | |||||
Total Assets | 3.97B | 3.27B | 3.04B | 3.33B | 2.60B |
Cash, Cash Equivalents and Short-Term Investments | 769.21M | 1.05B | 1.29B | 1.77B | 2.03B |
Total Debt | 25.78M | 137.98M | 29.58M | 11.21M | 7.24M |
Total Liabilities | 200.19M | 351.03M | 295.04M | 222.88M | 97.23M |
Stockholders Equity | 3.77B | 2.92B | 2.75B | 3.11B | 2.50B |
Cash Flow | |||||
Free Cash Flow | -408.97M | -539.79M | -510.66M | -861.66M | -517.18M |
Operating Cash Flow | -178.83M | -177.93M | -200.66M | -196.85M | -212.57M |
Investing Cash Flow | 275.91M | -259.78M | 229.15M | -1.35B | 629.70M |
Financing Cash Flow | -213.79M | 108.66M | -9.22M | 668.85M | 1.53B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | HK$8.07B | ― | -3.29% | ― | 3.76% | -833.33% | |
55 Neutral | HK$7.51B | ― | -8.04% | ― | 66.72% | 33.68% | |
55 Neutral | HK$6.94B | ― | -22.23% | ― | -14.17% | 76.00% | |
52 Neutral | $7.45B | 0.27 | -61.87% | 2.30% | 16.62% | 1.04% | |
51 Neutral | HK$8.90B | ― | -51.40% | ― | 58.75% | -1310.16% | |
48 Neutral | HK$1.34B | ― | -12.04% | ― | 260.78% | 40.04% | |
HK$7.04B | 82.07 | 4.95% | ― | ― | ― |
Ocumension Therapeutics has announced changes to its Nomination Committee in response to upcoming amendments to the Corporate Governance Code. Dr. Qin XIE and Mr. Ting Yuk Anthony WU have been appointed as new members, effective June 30, 2025, enhancing the committee’s composition with a blend of independent and non-executive directors.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics has announced the composition of its board of directors and the roles of each member, highlighting the leadership structure and committee memberships. This announcement provides clarity on the governance of the company, which is crucial for stakeholders to understand the decision-making framework and oversight within the organization.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics has updated the terms of reference for its Nomination Committee, which is responsible for identifying and recommending candidates for the company’s board of directors. This move is part of the company’s efforts to ensure compliance with applicable laws and listing standards, and to enhance the governance process by including a diverse and independent board composition.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics announced the cancellation and re-granting of options as part of its 2021 Share Option Scheme. The company canceled 4,018,842 options and re-granted 2,813,189 replacement options to 155 existing grantees, representing approximately 0.35% of the total shares. Additionally, Ocumension granted 15,462,865 new options and 8,952,185 awards to 430 grantees as further incentives, representing 1.90% and 1.10% of the total shares, respectively. This move aims to provide meaningful incentives and retain key personnel by aligning the exercise price with the prevailing market price of shares.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics announced that all resolutions proposed at their Annual General Meeting on June 19, 2025, were passed as ordinary resolutions. Key resolutions included the re-election of directors, the re-appointment of auditors, and the authorization for the board to manage shares, reflecting strong shareholder support and potentially enhancing the company’s governance and operational capabilities.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics has received authorization to initiate a phase III clinical trial for OT-802, a self-developed treatment for presbyopia, in China. This development underscores the company’s research capabilities and highlights the significant commercial potential in the underserved presbyopia treatment market in the region.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics announced that its product OT-703, an injectable fluocinolone intravitreal implant for diabetic macular edema, has been approved for a real-world study in Hainan, China. This approval marks a significant step in the company’s efforts to expand its presence in the Asian market, following its exclusive licensing agreement with Alimera Sciences for the development and commercialization of ILUVIEN in Greater China and other regions.
The most recent analyst rating on (HK:1477) stock is a Buy with a HK$7.29 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
Ocumension Therapeutics has announced its upcoming annual general meeting scheduled for June 19, 2025, in Shanghai. The meeting will address several key resolutions, including the adoption of the company’s financial statements for 2024, the re-election of directors, and the reappointment of Deloitte Touche Tohmatsu as auditors. Additionally, the meeting will consider authorizing the board to issue additional shares, which could impact the company’s capital structure and market operations.